NEWS & RELEASES

News and information about DAMIAN and Primary Aldosteronism. 

At DAMIAN, we’re about passion, not convenience.

Teresa Gerlock
Chief Operating Officer
  • DAMIAN clinical plan affirmed by the Foundation for Therapeutic Research

    The Lausanne-based Foundation for Therapeutic Research awards a grant for the development of new therapeutic principles in cardiovascular disease to the University of Torino to investigate DP13. The grant supports the Phase I clinical trial of DP13, the first-in-class aldosterone synthase inhibitor from DAMIAN.

  • DAMIAN conducts Phase I study of DP13 

    DAMIAN executes its Phase I proof-of-concept, double-blind, safety and tolerability study of DP13 in healthy volunteers (NCT03046589). The Phase I study successfully completed in September 2018.

  • DAMIAN initiates Phase II study of DP13 

    DAMIAN enrolls the first patients in its multinational Phase II study of DP13 in patients with Primary Aldosteronism (NCT04007406; EUDRACT# 2019-000919-85).

  • DAMIAN receives research grant from Innosuisse (formerly CTI)

    Innosuisse awards second Swiss research grant to DAMIAN to support the further development of its diagnostic tool, DP14. The new funding follows the successful completion of the design phase and allows the team to execute the in vivo proof-of-concept experiments.